
Sagar S. Patel
Examiner (ID: 4191)
| Most Active Art Unit | 1626 |
| Art Unit(s) | 1626 |
| Total Applications | 643 |
| Issued Applications | 430 |
| Pending Applications | 77 |
| Abandoned Applications | 159 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20172910
[patent_doc_number] => 12391641
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-08-19
[patent_title] => Prostaglandin EP
[patent_app_type] => utility
[patent_app_number] => 17/767188
[patent_app_country] => US
[patent_app_date] => 2020-10-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27897
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17767188
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/767188 | Prostaglandin EP | Oct 8, 2020 | Issued |
Array
(
[id] => 18338153
[patent_doc_number] => 20230130102
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-27
[patent_title] => Na/K-ATPase LIGANDS AND USE THEREOF FOR TREATMENT OF CANCER
[patent_app_type] => utility
[patent_app_number] => 17/767276
[patent_app_country] => US
[patent_app_date] => 2020-10-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17097
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17767276
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/767276 | Na/K-ATPase LIGANDS AND USE THEREOF FOR TREATMENT OF CANCER | Oct 7, 2020 | Abandoned |
Array
(
[id] => 16597931
[patent_doc_number] => 20210024462
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-28
[patent_title] => SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B
[patent_app_type] => utility
[patent_app_number] => 17/065463
[patent_app_country] => US
[patent_app_date] => 2020-10-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39055
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 330
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17065463
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/065463 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | Oct 6, 2020 | Abandoned |
Array
(
[id] => 18034557
[patent_doc_number] => 20220378772
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-01
[patent_title] => PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS
[patent_app_type] => utility
[patent_app_number] => 17/766161
[patent_app_country] => US
[patent_app_date] => 2020-10-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 89003
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 1321
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17766161
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/766161 | Prostaglandin E | Oct 1, 2020 | Issued |
Array
(
[id] => 19809492
[patent_doc_number] => 12240863
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-03-04
[patent_title] => Organometallic compound, organic light-emitting device including the same, and electronic apparatus including the organic light-emitting device
[patent_app_type] => utility
[patent_app_number] => 17/036694
[patent_app_country] => US
[patent_app_date] => 2020-09-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 17941
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 1462
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17036694
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/036694 | Organometallic compound, organic light-emitting device including the same, and electronic apparatus including the organic light-emitting device | Sep 28, 2020 | Issued |
Array
(
[id] => 18187481
[patent_doc_number] => 11578049
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-02-14
[patent_title] => Benzoic acid compound and method for preparing the same
[patent_app_type] => utility
[patent_app_number] => 17/026339
[patent_app_country] => US
[patent_app_date] => 2020-09-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 4647
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17026339
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/026339 | Benzoic acid compound and method for preparing the same | Sep 20, 2020 | Issued |
Array
(
[id] => 18980084
[patent_doc_number] => 11905244
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-20
[patent_title] => Chemical modulators of store-operated calcium channels and their therapeutic applications
[patent_app_type] => utility
[patent_app_number] => 17/025940
[patent_app_country] => US
[patent_app_date] => 2020-09-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 25
[patent_no_of_words] => 8246
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 94
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17025940
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/025940 | Chemical modulators of store-operated calcium channels and their therapeutic applications | Sep 17, 2020 | Issued |
Array
(
[id] => 16748772
[patent_doc_number] => 20210100781
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-08
[patent_title] => TUMOR SUPPRESSION
[patent_app_type] => utility
[patent_app_number] => 17/024435
[patent_app_country] => US
[patent_app_date] => 2020-09-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7008
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17024435
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/024435 | Tumor suppression | Sep 16, 2020 | Issued |
Array
(
[id] => 18271693
[patent_doc_number] => 20230092935
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-23
[patent_title] => CERIUM (IV) COMPLEXES AND THEIR USE IN ORGANIC ELECTRONICS
[patent_app_type] => utility
[patent_app_number] => 17/641129
[patent_app_country] => US
[patent_app_date] => 2020-09-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13085
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17641129
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/641129 | Cerium (IV) complexes and their use in organic electronics | Sep 6, 2020 | Issued |
Array
(
[id] => 16692451
[patent_doc_number] => 20210074930
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-11
[patent_title] => SYNTHESIS OF FT4-BASED ORGANIC SEMICONDUCTING SMALL MOLECULES BY PD-CATALYZED DIRECT (HETERO)ARYLATION OR DIRECT ALKENYLATION
[patent_app_type] => utility
[patent_app_number] => 17/012736
[patent_app_country] => US
[patent_app_date] => 2020-09-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8156
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17012736
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/012736 | SYNTHESIS OF FT4-BASED ORGANIC SEMICONDUCTING SMALL MOLECULES BY PD-CATALYZED DIRECT (HETERO)ARYLATION OR DIRECT ALKENYLATION | Sep 3, 2020 | Abandoned |
Array
(
[id] => 18027762
[patent_doc_number] => 11510923
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-29
[patent_title] => Ruxolitinib formulation for reduction of itch in atopic dermatitis
[patent_app_type] => utility
[patent_app_number] => 17/012691
[patent_app_country] => US
[patent_app_date] => 2020-09-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 33
[patent_figures_cnt] => 33
[patent_no_of_words] => 48773
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 150
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17012691
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/012691 | Ruxolitinib formulation for reduction of itch in atopic dermatitis | Sep 3, 2020 | Issued |
Array
(
[id] => 16512884
[patent_doc_number] => 20200392142
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-17
[patent_title] => CDK2/4/6 Inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/005233
[patent_app_country] => US
[patent_app_date] => 2020-08-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 62725
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 342
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17005233
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/005233 | CDK2/4/6 inhibitors | Aug 26, 2020 | Issued |
Array
(
[id] => 16512879
[patent_doc_number] => 20200392137
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-17
[patent_title] => TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING HETEROATOM-LINKED AROMATIC MOIETIES, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR
[patent_app_type] => utility
[patent_app_number] => 17/003385
[patent_app_country] => US
[patent_app_date] => 2020-08-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14483
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 10
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17003385
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/003385 | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor | Aug 25, 2020 | Issued |
Array
(
[id] => 18070540
[patent_doc_number] => 11529356
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-12-20
[patent_title] => 2-(morpholin-4-yl)-1,7-naphthyridines
[patent_app_type] => utility
[patent_app_number] => 16/999832
[patent_app_country] => US
[patent_app_date] => 2020-08-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 85478
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16999832
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/999832 | 2-(morpholin-4-yl)-1,7-naphthyridines | Aug 20, 2020 | Issued |
Array
(
[id] => 16466667
[patent_doc_number] => 20200368204
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-26
[patent_title] => COMPOUNDS FOR INHIBITING NS3 AND COMPOSITIONS CONTAINING THE INHIBITED PROTEIN
[patent_app_type] => utility
[patent_app_number] => 16/986863
[patent_app_country] => US
[patent_app_date] => 2020-08-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15894
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16986863
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/986863 | Compounds for inhibiting NS3 and compositions containing the inhibited protein | Aug 5, 2020 | Issued |
Array
(
[id] => 17828363
[patent_doc_number] => 20220265667
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-25
[patent_title] => ETIFOXINE FOR USE IN THE TREATMENT OF DISEASES RELATED TO ACTIVATED MAST CELLS
[patent_app_type] => utility
[patent_app_number] => 17/632592
[patent_app_country] => US
[patent_app_date] => 2020-08-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27905
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17632592
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/632592 | ETIFOXINE FOR USE IN THE TREATMENT OF DISEASES RELATED TO ACTIVATED MAST CELLS | Aug 5, 2020 | Abandoned |
Array
(
[id] => 20402218
[patent_doc_number] => 12492186
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-09
[patent_title] => Bicyclic heterocyclic compounds useful as IRAK4 inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/632811
[patent_app_country] => US
[patent_app_date] => 2020-08-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13754
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 346
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17632811
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/632811 | Bicyclic heterocyclic compounds useful as IRAK4 inhibitors | Aug 4, 2020 | Issued |
Array
(
[id] => 17851760
[patent_doc_number] => 20220281802
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-08
[patent_title] => COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF THEIR USE IN THE INHIBITION OF INTERACTION BETWEEN IL18 AND IL18R
[patent_app_type] => utility
[patent_app_number] => 17/631972
[patent_app_country] => US
[patent_app_date] => 2020-07-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17482
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -72
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17631972
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/631972 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF THEIR USE IN THE INHIBITION OF INTERACTION BETWEEN IL18 AND IL18R | Jul 30, 2020 | Pending |
Array
(
[id] => 17734590
[patent_doc_number] => 20220220049
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-14
[patent_title] => ORGANIC COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE AND ELECTRONIC APPARATUS
[patent_app_type] => utility
[patent_app_number] => 17/623772
[patent_app_country] => US
[patent_app_date] => 2020-07-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15062
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17623772
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/623772 | Organic compound, organic electroluminescent device and electronic apparatus | Jul 23, 2020 | Issued |
Array
(
[id] => 16436997
[patent_doc_number] => 20200354323
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-12
[patent_title] => SYNTHESES OF N-HETEROCYCLIC CARBENES AND INTERMEDIATES THEREFOR
[patent_app_type] => utility
[patent_app_number] => 16/936725
[patent_app_country] => US
[patent_app_date] => 2020-07-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13644
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16936725
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/936725 | Syntheses of N-heterocyclic carbenes and intermediates therefor | Jul 22, 2020 | Issued |